BRI and Heart Disease Risk: What 2024–2025 Research Reveals
Key Takeaways
- Cardiovascular disease (CVD) remains the leading cause of death globally, and visceral fat is a key driver
- BMI cannot detect the “normal weight obese” phenotype — people with normal body weight but dangerous abdominal fat distribution
- Multiple studies indicate BRI predicts cardiovascular events with greater accuracy than BMI, particularly in people with typical body weights
- A 2025 prospective cohort study from the China Kadoorie Biobank found significant associations between BRI and CVD incidence
- BRI is one monitoring tool among many — it does not replace clinical assessment of blood pressure, cholesterol, and blood glucose
The Hidden Cardiovascular Risk That BMI Misses
Cardiovascular disease kills approximately 17.9 million people per year worldwide — accounting for 32% of all global deaths, according to the World Health Organization.[1] Despite decades of research and improvement in treatment, prevention remains the most powerful lever.
The problem is that risk stratification tools haven’t kept pace with what we understand about metabolic disease. BMI — a simple weight-to-height ratio — is still the most commonly used screening metric in clinical practice and population health. But BMI has a fundamental blind spot: it cannot see where fat is located in the body.
Two people with the same BMI of 26 can have dramatically different cardiovascular risk profiles depending on where their fat is distributed. One might carry their weight in the hips and thighs (subcutaneous fat). The other might carry it in the abdomen, surrounding their heart, liver, and arteries (visceral fat). The second person faces substantially higher cardiometabolic risk — but BMI marks them identically.
BRI was designed to address precisely this gap.
How Visceral Fat Damages the Heart
Visceral adipose tissue (VAT) is not metabolically passive. It actively disrupts cardiovascular health through several interlocking mechanisms:
Chronic inflammation: Visceral fat releases pro-inflammatory cytokines — particularly IL-6 (interleukin-6) and TNF-α (tumor necrosis factor-alpha). These compounds promote endothelial dysfunction, the impairment of the inner lining of blood vessels that is the earliest stage of atherosclerosis.[2]
Dyslipidemia: Visceral fat depots drain into the portal vein and directly deliver free fatty acids to the liver. This drives the liver to produce excess triglycerides and very-low-density lipoprotein (VLDL), while suppressing HDL (“good cholesterol”). The resulting lipid profile — high triglycerides, low HDL, elevated LDL particle number — is a recognized cardiac risk pattern.[3]
Insulin resistance: Visceral fat impairs insulin signaling in the liver and skeletal muscle. Elevated fasting insulin and blood glucose, even below the diagnostic threshold for diabetes, are independent risk factors for coronary artery disease.
Elevated blood pressure: Visceral fat contributes to hypertension through multiple pathways, including activation of the renin-angiotensin-aldosterone system (RAAS) and increased sympathetic nervous system activity.
Direct pericardial fat: Fat depots surrounding the heart (epicardial and pericardial fat) have been shown to directly impair cardiac function and are strongly correlated with overall visceral fat burden.[4]
Why Standard Metrics Fail Cardiovascular Risk Patients
The Normal Weight Obesity Problem
One of the most clinically significant gaps in cardiovascular risk assessment is the normal weight obese (NWO) phenotype. Studies suggest that 20–30% of adults with a BMI in the “normal” range (18.5–24.9) have visceral fat levels associated with metabolic dysfunction and cardiovascular risk.[5]
These individuals are not flagged by BMI. They may not have diabetes, hypertension, or dyslipidemia — yet. But their underlying visceral fat burden is progressing quietly. By the time conventional risk factors appear, years of vascular damage may already have occurred.
BRI is more likely to identify this phenotype because it incorporates waist circumference, which correlates with visceral fat accumulation independently of body weight.
The Muscular Athlete Problem
On the other end of the spectrum, highly muscular individuals — athletes, manual workers — may have BMI values in the overweight range (25–29.9) due to high muscle mass. Standard risk models flag them as elevated risk based on BMI alone. BRI, which is based on waist circumference rather than weight, typically scores these individuals in the normal range, reflecting their actual cardiometabolic profile more accurately.
What Recent Research Shows
China Kadoorie Biobank 2025
A 2025 prospective cohort study published in JACC: Asia using data from the China Kadoorie Biobank — one of the largest prospective studies of adult health in the world — examined the association between BRI and incident cardiovascular disease.[6] The study followed a large cohort over multiple years, tracking CVD events including coronary heart disease and stroke.
The findings reinforced what smaller studies had suggested: BRI showed significant associations with cardiovascular disease incidence, and its predictive performance compared favorably to BMI in identifying individuals at elevated risk, particularly in the context of abdominal fat distribution.
Existing Meta-Analytic Evidence
Prior to the 2025 cohort data, several systematic reviews and meta-analyses had already established BRI as a cardiovascular risk predictor. Research published in multiple cardiology and public health journals found:
- Higher BRI scores were consistently associated with greater risk of hypertension, type 2 diabetes, and cardiovascular events across diverse populations
- BRI outperformed BMI in identifying metabolically unhealthy individuals within normal BMI categories
- BRI showed similar or stronger associations with CVD risk than waist-to-height ratio, which is currently considered one of the better simple anthropometric predictors
Harvard Health Publishing has also highlighted this body of evidence, noting that “body roundness may predict heart disease risk” in accessible summaries of recent research.[7]
BRI Levels and Cardiovascular Risk: A Practical Interpretation
The following table represents current research understanding of BRI and cardiovascular risk. These are population-level associations, not individual diagnoses.
| BRI Score | Risk Interpretation |
|---|---|
| Below 2.0 | Possibly underweight; very low visceral fat |
| 2.0 – 3.5 | Low cardiovascular risk from visceral fat perspective |
| 3.5 – 5.0 | Moderate risk; waist circumference warrants attention |
| 5.0 – 6.9 | Elevated risk; lifestyle modification strongly recommended |
| Above 6.9 | High risk; clinical assessment of cardiovascular risk factors advised |
Important context: BRI is a screening indicator, not a risk score. A BRI of 5.5 does not mean you will develop heart disease. It means the pattern of fat distribution associated with that BRI score is, in populations, linked to higher cardiovascular incidence. Individual risk depends on many other factors.
BRI Alongside Other Cardiovascular Markers
BRI should be used as part of a broader picture, not in isolation. The biomarkers most relevant to cardiovascular risk, alongside BRI:
| Marker | What It Measures | Target (general reference) |
|---|---|---|
| BRI | Body shape / visceral fat proxy | 2.0 – 3.5 (low risk) |
| Blood pressure | Arterial load on the heart | <120/80 mmHg |
| LDL cholesterol | Atherogenic lipid particles | <100 mg/dL (primary prevention) |
| Triglycerides | Blood fat linked to visceral adiposity | <150 mg/dL |
| HDL cholesterol | Protective cholesterol | >40 mg/dL (men), >50 mg/dL (women) |
| Fasting glucose | Insulin resistance indicator | <100 mg/dL |
| hsCRP | Systemic inflammation marker | <1.0 mg/L (optimal) |
A person with BRI of 4.8, elevated triglycerides, borderline fasting glucose, and elevated hsCRP presents a very different risk picture than someone with the same BRI but all other markers in normal ranges. This is why BRI functions best as a flag that prompts further evaluation, not as a definitive risk determination.
What You Can Do
If your BRI is trending upward or sits above 4.0, the most evidence-backed actions target visceral fat reduction directly:
Dietary intervention: The Mediterranean dietary pattern has the strongest evidence base for reducing visceral fat and cardiovascular risk simultaneously. A large meta-analysis found adherence to Mediterranean-style eating reduced major cardiovascular events by 30% compared to a low-fat control diet.[8]
Aerobic exercise: Both moderate-intensity continuous exercise (150+ minutes per week of brisk walking, cycling, swimming) and high-intensity interval training have demonstrated visceral fat reduction and improved cardiovascular risk markers in clinical trials.
Reducing refined carbohydrates and added sugar: High intake of sugar-sweetened beverages and refined carbohydrates is specifically linked to visceral fat accumulation and elevated triglycerides.
Alcohol reduction: Even moderate alcohol intake has been shown to preferentially promote visceral fat storage. Reducing or eliminating alcohol is one of the most direct dietary changes affecting abdominal fat.
Sleep: Consistently short sleep (under 6 hours) dysregulates cortisol, ghrelin, and leptin — all of which contribute to abdominal fat gain. Prioritizing 7–9 hours meaningfully affects visceral fat trajectory over time.
For detailed protocols and expected timelines, see How to Lower Your BRI: Evidence-Based Strategies.
Medical Disclaimer
This article is for informational and educational purposes only. It does not constitute medical advice, clinical diagnosis, or treatment recommendation. Cardiovascular disease is a complex medical condition requiring professional evaluation. If you are concerned about your heart health or cardiovascular risk, consult a qualified physician or cardiologist. Do not discontinue or modify medications or medical treatment based on information in this article. BRI is a screening tool and does not replace clinical assessment of cardiovascular risk factors.
Frequently Asked Questions
Can a high BRI predict a heart attack?
No. BRI identifies a body fat distribution pattern associated — at the population level — with elevated cardiovascular risk. It does not predict individual events. Many people with high BRI scores never experience cardiovascular disease; many people with low BRI scores do. Risk is multifactorial. BRI is one data point among many that should be evaluated in context.
Is BRI better than waist circumference alone for heart risk?
BRI incorporates waist circumference scaled to height, which makes it more equitable across individuals of different statures. Research suggests BRI and waist-to-height ratio perform similarly for cardiovascular risk stratification — both outperforming simple waist circumference or BMI. The advantage of BRI is that it provides a single normalized score that is comparable across populations.
How quickly can cardiovascular risk markers improve if I lower my BRI?
Studies show that 12 weeks of consistent dietary change and aerobic exercise can produce meaningful reductions in visceral fat, with corresponding improvements in triglycerides, blood pressure, insulin sensitivity, and inflammatory markers. Waist circumference (and therefore BRI) typically begins declining within 4–8 weeks of sustained caloric adjustment and exercise, though individual responses vary considerably.
Should I worry about a high BRI if my cholesterol and blood pressure are normal?
A high BRI with otherwise normal cardiovascular markers may indicate early-stage visceral fat accumulation before metabolic dysregulation has fully manifested. This is actually the ideal time to act — before markers like fasting glucose, triglycerides, or blood pressure begin shifting. Discuss your BRI trend and lifestyle factors with your healthcare provider.
Does BRI apply equally to men and women?
Visceral fat distribution differs significantly between men and women, particularly before and after menopause. Men tend to accumulate visceral fat earlier and more readily. Women shift toward central adiposity after menopause due to declining estrogen. Some researchers argue that sex-specific BRI thresholds should be applied, though universal cutoffs are currently more common in the literature. Age-adjusted interpretation is covered in our BRI by Age guide.
Is there a safe lower limit for BRI?
A BRI below 2.0 is associated with very low body roundness and may indicate underweight status, which carries its own set of cardiovascular and health risks. The apparent “U-shaped” relationship between BRI and mortality risk — where both very low and very high BRI scores associate with higher risk — has been observed in several large cohort studies. This underscores that maintaining a BRI in the 2.0–4.0 range is the target, not simply minimizing BRI.
References
World Health Organization. “Cardiovascular Diseases (CVDs) Fact Sheet.” WHO. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Libby P, Ridker PM, Hansson GK. “Progress and challenges in translating the biology of atherosclerosis.” Nature. 2011;473(7347):317–325. doi:10.1038/nature10146
Desprès JP, Lemieux I. “Abdominal obesity and metabolic syndrome.” Nature. 2006;444(7121):881–887. doi:10.1038/nature05488
Iacobellis G, Corradi D, Sharma AM. “Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart.” Nature Clinical Practice Cardiovascular Medicine. 2005;2(10):536–543. doi:10.1038/ncpcardio0319
Romero-Corral A, Somers VK, Sierra-Johnson J, et al. “Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality.” European Heart Journal. 2010;31(6):737–746. doi:10.1093/eurheartj/ehp487
Li Y, et al. “Body Roundness Index and Incident Cardiovascular Disease: A China Kadoorie Biobank Prospective Cohort Study.” JACC: Asia. 2025. doi:10.1016/j.jacasi.2025.05.014
Harvard Health Publishing. “Body roundness index may predict heart disease risk.” Harvard Medical School. 2024. Available at: https://www.health.harvard.edu/heart-health/body-roundness-index-may-predict-heart-disease-risk
Estruch R, Ros E, Salas-Salvadó J, et al. “Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.” New England Journal of Medicine. 2018;378(25):e34. doi:10.1056/NEJMoa1800389
Related Articles
- Visceral Fat: What It Is, Why It’s Dangerous, and How BRI Measures It — Deep dive into the fat type most directly linked to cardiovascular disease
- BRI and Cancer Risk: What 2024–2025 Research Shows — How the same visceral fat mechanisms connect to cancer risk
- How to Lower Your BRI: Evidence-Based Strategies — Specific interventions for reducing abdominal fat and cardiovascular risk